Literature DB >> 11232699

Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?

J F Cadranel1, E Lebiez, V Di Martino, B Bernard, S El Koury, A Tourbah, B Pidoux, D Valla, P Opolon.   

Abstract

OBJECTIVES: Focal neurological signs have been poorly documented in the course of hepatic encephalopathy in cirrhotic patients because they are not mentioned in any textbooks of liver diseases. Having the opportunity to observe such cases, we underwent a prospective study to determine incidence, characteristics, associated factors, prognostic significance, and outcome of this rare form of hepatic encephalopathy.
METHODS: Over a 12-month period, all cirrhotic patients hospitalized in the intensive care unit of our department for hepatic encephalopathy were prospectively studied. Patients with clinical and electroencephalogram evidences of hepatic encephalopathy were examined by a senior physician and, in cases of focal neurological signs, underwent examination by a neurologist, CT scan, lumbar punction, and cerebral magnetic resonance imaging and echo Doppler examination of neck and head vessels. Clinical and biological parameters were compared in patients during episodes with and without focal neurological signs, and outcome was noted.
RESULTS: Thirty-four cirrhotic patients were hospitalized for 48 episodes of hepatic encephalopathy; two of these patients with cerebral hematoma were excluded. Twenty-four patients exhibited 38 hepatic encephalopathy episodes without focal neurological signs (82.6%), and eight patients exhibited eight hepatic encephalopathy episodes with focal neurological signs (17.4%) that were hemiplegia and hemiparesia in six patients (75%). In all patients, cerebral CT scan and cerebrospinal fluid examination disclosed no abnormalities, as neither did cerebral magnetic resonance imaging (n = 5) and echo Doppler examination of neck and head vessels (n = 5). Except for female sex, which was more often encountered in patients with focal neurological signs (p < 0.05), there were no differences between episodes with and without focal neurological signs for any of the parameters studied. In surviving patients who recovered from hepatic encephalopathy (7/8), focal neurological signs disappeared without recurrences after follow up of 6 months (3-12).
CONCLUSIONS: Hepatic encephalopathy with focal neurological signs when carefully searched is not uncommon. It could be more frequent in cirrhotic females, is reversible, and has no prognostic significance.

Entities:  

Mesh:

Year:  2001        PMID: 11232699     DOI: 10.1111/j.1572-0241.2001.03552.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 2.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

Review 3.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

4.  Liver transplantation nearly normalizes brain spontaneous activity and cognitive function at 1 month: a resting-state functional MRI study.

Authors:  Yue Cheng; Lixiang Huang; Xiaodong Zhang; Jianhui Zhong; Qian Ji; Shuangshuang Xie; Lihua Chen; Panli Zuo; Long Jiang Zhang; Wen Shen
Journal:  Metab Brain Dis       Date:  2015-02-24       Impact factor: 3.584

5.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

Review 6.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06

7.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 8.  Intensive Care Management of Patients with Cirrhosis.

Authors:  Jody C Olson
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06

Review 9.  Management of Neurologic Manifestations in Patients with Liver Disease.

Authors:  José M Ferro; Pedro Viana; Patrícia Santos
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.598

10.  Clinical manifestations of portal hypertension.

Authors:  Said A Al-Busafi; Julia McNabb-Baltar; Amanda Farag; Nir Hilzenrat
Journal:  Int J Hepatol       Date:  2012-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.